US 11,890,282 B2
Method of reducing pulmonary exacerbations in respiratory disease patients
Sanjeev Ahuja, Carmel, IN (US); Ralph Grosswald, Alpharetta, GA (US); Gregory S. Duncan, Atlanta, GA (US); and Eric B. Springman, Atlanta, GA (US)
Assigned to Celltaxis, LLC, Atlanta, GA (US)
Filed by CELLTAXIS, LLC, Atlanta, GA (US)
Filed on Jan. 11, 2021, as Appl. No. 17/145,586.
Application 17/145,586 is a continuation of application No. 16/427,571, filed on May 31, 2019, granted, now 10,898,484.
Claims priority of provisional application 62/678,964, filed on May 31, 2018.
Claims priority of provisional application 62/702,038, filed on Jul. 23, 2018.
Prior Publication US 2021/0236484 A1, Aug. 5, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4985 (2006.01); A61P 11/00 (2006.01); A61K 31/47 (2006.01); A61K 31/519 (2006.01); A61K 45/06 (2006.01)
CPC A61K 31/4985 (2013.01) [A61K 31/47 (2013.01); A61K 31/519 (2013.01); A61P 11/00 (2018.01); A61K 45/06 (2013.01); A61K 2121/00 (2013.01)] 24 Claims
 
1. A method of reducing pulmonary exacerbations in a cystic fibrosis patient, wherein the patient is undergoing concomitant treatment with a CFTR modulator and wherein the patient has an FEV1pp greater than or equal to about 68% at baseline, the method comprising orally administering to the patient acebilustat at a total daily dose of about 100 mg or less, and wherein the CFTR modulator is selected from the group consisting of ivacaftor, lumacaftor, tezacaftor, VX-445, VX-659, VX-440 and VX-152, or a combination of any of thereof.